With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...